With 37 years of clinical trial experience, Peter J. McDonnell, MD, offer some tips.
Modern Retina Spring 2024
After 3 loading doses, the patients were randomly assigned to receive EYP-1901 or continue to receive aflibercept at an 8-week dosing pattern for 32 weeks.
A review of the phase 4 PALADIN data show that steroid-eluting implants lead to good vision, safe outcomes, and reduced burden in patients with DME.
It is important that the ophthalmic community redouble our efforts in following patients with age-related macular degeneration (AMD) using optical coherence tomography (OCT) to find the early signs of geographic atrophy (GA).
Gildeuretinol halts Stargardt disease progression for up to 6 years.
When we discuss trial participation with patients, we stress that the goal of these studies is to obtain better visual outcomes and ease the treatment burden.
Advances in virtual reality and AI are helping those with AMD and low vision.
Advertisement
Advertisement
Trending on Modern Retina
1
Frank Holz, MD, FEBO, FARVO, highlights new treatment developments at EURETINA
2
Challenges Reported by Young Physicians in Managing Geographic Atrophy and How these Shape Patient Care
3
The Retina TL;DR: Advancing sustained VEGF suppression with EYP-1901 with Jay S. Duker, MD
4
Increasing the knowledge base of GA is key to individualizing patient therapy
5
